Kontogianni-Katsarou K, Lariou C, Tsompanaki E, Vourlakou C, Kairi-Vassilatou E, Mastoris C, Pantazi G, Kondi-Pafiti A. KIT-negative gastrointestinal stromal tumors with a long term follow-up: A new subgroup does exist. World J Gastroenterol 2007; 13(7): 1098-1102 [PMID: 17373746 DOI: 10.3748/wjg.v13.i7.1098]
Corresponding Author of This Article
Katerina Kontogianni-Katsarou, MD, PhD, Department of Pathology, Athens Medical School, Areteion University Hospital, 1b, Agias Annis Str. 145 63, Kifisia, Greece. k.kontogianni@m2k.gr
Article-Type of This Article
Rapid Communication
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 21, 2007; 13(7): 1098-1102 Published online Feb 21, 2007. doi: 10.3748/wjg.v13.i7.1098
Table 1 Clinicopathological features of KIT-negative cases
CaseNo.
Sex
Age (yr)
Symptoms
Site
Size
Mitoses(/50 HPF)
Presenceof necrosis
Morphology
Risk category
Clinicalstatus
Survivaldata/mo
(cm)
1
M
60
Yes
Small Intestine
4.30
1
No
Epithelioid
Low risk
Primary
Alive/12
2
M
46
No
Stomach
0.50
0
No
Mixed
Very low risk
Primary
Alive/24
3
M
50
No
Small Intestine
0.50
0
No
Anaplastic
Very low risk
Primary
Alive/24
4
M
64
Yes
Large Intestine
4.50
10
Yes
Epithelioid
High risk
Liver metastasis
Dead/12
5
M
78
Yes
Small Intestine
7.00
1
Yes
Mixed
Intermediate risk
Liver metastasis
Dead/12
6
F
53
Yes
Stomach
5.00
0
No
Spindled
Low risk
Primary
Alive/47
7
M
43
Yes
Esophagus
7.00
0
No
Mixed
Intermediate risk
Primary
Alive/25
8
M
51
Yes
Small Intestine
6.00
2
Yes
Epithelioid
Intermediate risk
Primary
Alive/12
9
M
69
No
Stomach
2.00
0
No
Mixed
Very low risk
Primary
Alive/37
10
M
54
Yes
Stomach
3.50
0
No
Spindled
Low risk
Primary
Alive/62
11
M
70
Yes
Stomach
6.00
0
No
Anaplastic
Intermediate risk
Primary
Alive/82
12
M
42
Yes
Stomach
6.00
2
No
Anaplastic
Intermediate risk
Primary
Alive/56
13
M
26
No
Stomach
0.50
0
No
Epithelioid
Very low risk
Primary
Alive/78
14
M
82
Yes
Stomach
30.00
6
Yes
Mixed
High risk
Primary
Alive/82
15
M
61
Yes
Small Intestine
3.00
29
No
Mixed
High risk
Liver metastasis
Dead/2
Table 2 Correlation between gender and CD117 expression in patients with GISTs
CD117 expression
Negative
Positive
Total
Gender
Male
14
17
31
45.20%
54.80%
100%
Female
1
18
19
5.30%
94.70%
100%
Total
15
35
50
Table 3 Correlation between tumor location and CD117 expression in patients with GISTs
Tumor location
CD117 expression
Negative
Positive
Total
Esophagus
1
2
3
33.30%
66.70%
100%
Stomach
8
11
19
42.10%
57.90%
100%
Small intestine
5
18
23
21.70%
78.30%
100%
Large intestine
1
4
5
20%
80%
100%
Total
15
35
50
30%
70%
100%
Table 4 Immunohistohemical findings of patients with KIT-negative GISTs
Immunohistochemistry
CaseNo.
CD117
α-SMA
Desmin
S-100
NSE
CD34
1
Negative
Positive
Positive
-
-
Positive
2
Negative
-
Positive
Positive
-
-
3
Negative
-
-
-
-
Positive
4
Negative
Positive
-
-
-
Positive
5
Negative
Positive
-
-
Positive
-
6
Negative
-
-
Positive
Positive
-
7
Negative
Positive
Positive
Positive
-
-
8
Negative
Positive
-
-
-
Positive
9
Negative
Positive
Positive
-
Positive
-
10
Negative
-
-
Positive
Positive
Positive
11
Negative
-
-
-
-
Positive
12
Negative
-
-
-
-
Positive
13
Negative
Positive
Positive
-
-
-
14
Negative
Positive
-
-
Positive
Positive
15
Negative
Positive
-
Positive
-
-
Citation: Kontogianni-Katsarou K, Lariou C, Tsompanaki E, Vourlakou C, Kairi-Vassilatou E, Mastoris C, Pantazi G, Kondi-Pafiti A. KIT-negative gastrointestinal stromal tumors with a long term follow-up: A new subgroup does exist. World J Gastroenterol 2007; 13(7): 1098-1102